Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

lotho and Mesenchymal Stem Cells: A Review on Cell and Gene Therapy for Chronic Kidney Disease and Acute Kidney Diseas

Full text
Franco, Marcella Liciani [1] ; Beyerstedt, Stephany [1] ; Rangel, erika Bevilaqua [1, 2]
Total Authors: 3
[1] Hosp Israelita Albert Einstein, Albert Einstein Res & Educ Inst, BR-05652900 Sao Paulo - Brazil
[2] Univ Fed Sao Paulo, Nephrol Div, BR-04038901 Sao Paulo - Brazil
Total Affiliations: 2
Document type: Journal article
Source: PHARMACEUTICS; v. 14, n. 1 JAN 2022.
Web of Science Citations: 0

Chronic kidney disease (CKD) and acute kidney injury (AKI) are public health problems, and their prevalence rates have increased with the aging of the population. They are associated with the presence of comorbidities, in particular diabetes mellitus and hypertension, resulting in a high financial burden for the health system. Studies have indicated Klotho as a promising therapeutic approach for these conditions. Klotho reduces inflammation, oxidative stress and fibrosis and counter-regulates the renin-angiotensin-aldosterone system. In CKD and AKI, Klotho expression is downregulated from early stages and correlates with disease progression. Therefore, the restoration of its levels, through exogenous or endogenous pathways, has renoprotective effects. An important strategy for administering Klotho is through mesenchymal stem cells (MSCs). In summary, this review comprises in vitro and in vivo studies on the therapeutic potential of Klotho for the treatment of CKD and AKI through the administration of MSCs. (AU)

FAPESP's process: 21/02216-7 - Combined treatment with empagliflozin, caloric restriction, mesenchymal stem cells and Klotho for halting the progression of diabetic kidney disease and ameliorate acute kidney injury
Grantee:Érika Bevilaqua Rangel
Support Opportunities: Regular Research Grants
FAPESP's process: 17/23195-2 - Mesenchymal stem cell therapy for halting the progression of acute and chronic kidney injury and in vivo modulate kidney-derived c-Kit stem cells
Grantee:Érika Bevilaqua Rangel
Support Opportunities: Regular Research Grants